Prostate cancer: progression a main cause of surveillance dropout

  • Van Hemelrijck M & al.
  • Eur Urol
  • 29 Oct 2018

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Nearly 44% of men with prostate cancer drop out of active surveillance (AS) within 5 years, of whom 27.5% develop signs of disease progression.

Why this matters

  • A large number of patients opting out because of signs of disease progression highlights the need for improvement in patient selection for AS.

Study design

  • 10,296 men with prostate cancer on AS from Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database.
  • Funding: Movember Foundation.

Key results

  • 7049 men remained on AS during follow-up (>5 years follow-up, 2339;
  • The cumulative incidence rate of men who remained on AS was 56.4% during 5-year follow-up.
  • 43.6% of men discontinued AS or were lost to follow-up.
    • 27.5% showed signs of disease progression.
    • 12.8% switched to active treatment without evidence of progression.
    • 1.7% of men continued watchful waiting.
    • 1.7% died from other causes.
  • 10-year cumulative incidence of signs of disease progression was 38.2%.

Limitations

  • Heterogeneity in study protocols and data collection across centers.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit